NCT05385055 is a clinical trial of THS use in Inflammation, sponsored by Philip Morris Products S.A..

Who is sponsoring NCT05385055?

NCT05385055 is sponsored by Philip Morris Products S.A..

What drugs are being tested in NCT05385055?

Interventions in NCT05385055: THS use, Cigarette smoking, Smoking abstinence.

What condition does NCT05385055 study?

NCT05385055 studies Inflammation, Oxidative Stress, Smoking, Smoking Abstinence.

Is NCT05385055 still recruiting?

NCT05385055 is currently completed. Last updated 4 September 2024.

Last reviewed 2024-09-04 · How we verify

NCT05385055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction of Exposure, Inflammation, and Oxidative Stress Following At Least 2 Years of Switching to THS Use Compared to Cigarette Smoking

Completed Last updated 4 September 2024

What this trial tests

trial testing THS use in Inflammation in 952 participants. Completed in 23 April 2024.

Timeline

13 June 2022

Primary endpoint
27 December 2023

23 April 2024

Quick facts

Lead sponsor	Philip Morris Products S.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	952
Start date	13 June 2022
Primary completion	27 December 2023
Estimated completion	23 April 2024
Sites	37 locations across Japan, Greece, Germany, Poland, Bulgaria, Czechia

Drugs / interventions tested

THS use
Cigarette smoking
Smoking abstinence

Conditions studied

Inflammation — all drugs for Inflammation →
Oxidative Stress — all drugs for Oxidative Stress →
Smoking — all drugs for Smoking →
Smoking Abstinence — all drugs for Smoking Abstinence →

Sponsor

Philip Morris Products S.A. — full company profile →

Who can join

Adults 30 to 60, any sex, with Inflammation or Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a cross-sectional 3-group study with subjects enrolled and matched by region (Asia, Europe), age, sex, and average daily product consumption over the last 2 years as self-reported. The study will be conducted as a multi-center and multi-regional study, to demonstrate beneficial effects of switching from cigarettes to THS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Differences in biomarkers of potential harm after 2+ years of tobacco heating system use compared to cigarette smoking: a cross-sectional study.
Ansari SM, Leroy P, de La Bourdonnaye G, Pouly S, et al · · 2025 · cited 5× · PMID 39882959 · DOI 10.1080/1354750x.2025.2461069

Verify or expand the search:

Other trials of THS use

Trials testing the same drug.

NCT05569005 — Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic · NA · terminated

Other recruiting trials for Inflammation

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07479940 — Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters · NA · active not recruiting
NCT07269847 — Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults · NA · recruiting
NCT07171450 — Cognitive Remediation · NA · recruiting
NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting

Other Philip Morris Products S.A. trials

Trials by the same sponsor.

NCT07443631 — Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants · NA · recruiting
NCT07459712 — Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to Cigarettes · NA · active not recruiting
NCT07408180 — Exploratory Randomized, Controlled, Dose-response Study on the Impact of Nicotine From Five Variants of a Nicotine Table · NA · active not recruiting
NCT07135648 — Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current Smokers · NA · active not recruiting
NCT06171490 — Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05385055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philip Morris Products S.A.
Last refreshed: 4 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05385055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing